Table 1.
Characteristic | Non-Hispanic Blacks (n = 1260) | Non-Hispanic Whites (n = 1500) | P value |
---|---|---|---|
Age, mean ± SD | 62.0 ± 7.0 | 62.5 ±7.3 | .08 |
Age, n (%) | .005 | ||
40–49 | 35 (2.8) | 57 (3.8) | |
50–59 | 481 (38.1) | 480 (32.0) | |
60–69 | 513 (40.7) | 658 (43.8) | |
70+ | 232 (18.4) | 307 (20.4) | |
Sex, n (%) | <.001 | ||
Female | 580 (46.0) | 567 (37.8) | |
Male | 680 (54.0) | 932 (62.2) | |
Missing | 0 | 1 | |
Education, n (%) | <.001 | ||
Less than high school | 493 (39.1) | 345 (23.0) | |
High-school graduate | 446 (35.4) | 543 (36.2) | |
More than high school | 274 (21.8) | 521 (34.7) | |
Other/Unknown | 47 (3.7) | 91 (6.1) | |
Insurance status, n (%) | <.001 | ||
Commercial | 424 (33.6) | 684 (45.6) | |
Free care | 59 (4.7) | 28 (1.9) | |
Medicaid | 355 (28.2) | 251 (16.7) | |
Medicare | 422 (33.5) | 537 (35.8) | |
Indication for baseline colonoscopy, n (%) | <.001 | ||
Screening | 652 (51.8) | 978 (65.2) | |
Surveillance | 608 (48.2) | 522 (34.8) | |
Findings at baseline colonoscopy, n (%) | .004 | ||
Normal/nonneoplastic polyps/othera | 360 (28.6) | 523 (34.9) | |
1–2 Nonadvanced neoplastic polypsb | 563 (44.7) | 607 (40.5) | |
Multiplicityc | 113 (9.0) | 108 (7.2) | |
Hyperplastic polyps ≥ 10 mm | 3 (0.2) | 11 (0.7) | |
Advanced adenomas and/or serrated polypsd | 206 (16.3) | 233 (15.5) | |
Malignant polypse | 15 (1.2) | 18 (1.2) | |
Surveillance interval, n (%) | .38 | ||
≤3 y | 304 (24.2) | 373 (25.0) | |
4–5 y | 349 (27.7) | 441 (29.5) | |
>5 y | 606 (48.1) | 680 (45.5) |
SD, standard deviation.
Patients undergoing repeat surveillance because of prior adenomas or serrated polyps.
Includes both nonadvanced adenomas and serrated polyps.
Multiplicity defined by the presence of ≥ 3 nonadvanced adenomas only; no patient had ≥ 3 nonadvanced serrated polyps.
Advanced adenomas defined by size ≥ 10 mm or the presence of villous histology or high grade dysplasia; advanced serrated polyps defined by size ≥ 10 mm, the presence of cytological dysplasia or a traditional serrated adenoma of any size.
Malignant polyps defined as advanced adenomas containing invasive cancer amenable to endoscopic polypectomy alone and negative surveillance at 3–6 months.